Embracing Emerging Technology

Our Core Bio-Sensing Technology Consists of Three Major Components:


Using raman technology to digitize bodily fluid.


Molecular fingerprinting to quantify results.


Proprietary machine learning algorithms.

Our Basic Process

Kaligia Biosciences’ Point of Care Technology

Kaligia Biosciences’ technology is based on in-vitro point-of-care devices, statistics-based algorithms, and analytics.

Kaligia Biosciences’s core bio-sensing technology sets us apart from the competition. Lasers and spectrometers provide a fingerprint that can identify various molecules. Unique data acquisition and machine learning algorithms provide rapid results.
Kaligia Biosciences’ RBA Whole Blood Hemoglobin Analyzer allows for results of similar efficacy to a CBC in under 3 minutes
Kaligia’s RBA Whole Blood Hemoglobin Analyzer is in Pre-FDA approval data collection for submission/clinical trials.
Kaligia’s RBA measurement devices allow for testing with various bodily fluids.

Product and Technology Development

Kaligia’s RBA device is in various stages of research and approval.

Rapid Biofluid Analyzer (RBA)

RBA is an in-vitro measurement device which is invasive for blood application and non-invasive for other bodily fluids such as saliva, urine and sweat. This lends to numerous potential applications in the biomedical field.


  • Whole Blood Hemoglobin Test
    – Hemoglobin (Hgb), Hematocrit (HCT), and Red Blood Cells (RBC)

  • COVID Rapid Screener
    – Glucose, Creatinine, Triglycerides, Cholesterol, Albumin, Total Protein

  • Serum (in R&D)
    – COVID-19, Influenza A, Influenza B

  • Urine (in R&D)


  • Portable Lab
  • Optimized for Operator Safety
  • Significantly decreased risk for contamination
  • Results in under 3 minutes
Never Stop Learning

Kaligia Biosciences’ Acquisition Software and Analytics

Kaligia Biosciences employs statistics-based algorithms to calculate quantitative results on biofluid composition. These proprietary algorithms are continuously being improved upon as more research is conducted within our CLIA-certified laboratory.

Kaligia Biosciences

Our Latest News


Company News

Kaligia Biosciences Completes Calibration Testing for the Latest RBA Device

October 11, 2022
Kaligia Biosciences’ Reagent-Free Whole Blood Hemoglobin Analyzer has been tested in conjunction with our collaborators…
Company News

Tampa Bay Company Develops Coronavirus Saliva Test

September 28, 2020
LARGO, Fla. — A Tampa Bay company is awaiting FDA approval for a COVID-19 testing…
Product Information

Kaligia Biosciences’ COVID-19 Rapid Biofluid Analyzer 2 Featured on ABC Action News

June 10, 2020
The co-founder and CEO of Kaligia Biosciences, Fazal Fazlin, spoke with ABC News regarding the…